

Advanced Informatics and
Technology for Biomarker
Discovery:

Disease-Associated Metabolites and Evidence of Infection in ME/CFS

Aleyna Lumsden



UK Research
and Innovation

Research Project | The ME Association

INTRODUCTION | ME, MY LAB, MY RESEARCH

- Second-year DPhil (PhD) student in the **Nuffield Department of Women's & Reproductive Health (NDWRH)**, University of Oxford
- My research is a joint project with the **Rosalind Franklin Institute (RFI)**
 - Multidimensional Imaging Team (MDI)
 - Mass Spectrometry group
- I also collaborate with **Imperial College** and the **National Phenome Centre (NPC)**



The Rosalind
Franklin Institute



National
Phenome
Centre

SUPERVISORS



Dr. Bela Paizs
Mass spectrometry
and computational
modelling



**Dr. Marcus
Gallagher-Jones**
Electron
microscopy



Prof. Karl Morten
ME/CFS and
biomarker
discovery

IMPERIAL



UNIVERSITY OF
OXFORD

RFI

"Finding new pathways to improve human health, transforming the impossible into reality"



TECHNOLOGY EXPERTISE



Oxford University | NDWRH

"Advancing women's and reproductive health through research and education"



DISEASE EXPERTISE

THE CHALLENGE OF ME/CFS | WHY ARE WE STILL STUCK?





BIOMARKERS | molecular disease signatures

Biomarkers

Biological molecules present in body fluids or tissues that is indicative of normal or abnormal biological processes, or of a disease or medical condition.

Why we need “biomarkers” for diseases?



Diagnosis



Stratification



Prognosis



Treatment
monitoring



Mechanistic
insights

A single biomarker is unlikely for a multisystem disease like ME/CFS; identifying a panel of interacting markers – a “disease fingerprint” – could enable translation.

7



METABOLOMICS | what small molecules can tell us


Metabolomics

The study of small molecules in our body (called **metabolites**) that reflect how our organs and cells are functioning.

Why study metabolites for diseases?



Dynamic



Functional



Directly reflects
biological activity

7

WHY WE NEED OUR NOVEL TECHNOLOGIES

- Metabolomics allows us to measure thousands of small molecules in the body – but we don't know the identity of many of them
- If we don't know what a molecule is, it is very difficult to understand what role it might play in ME/CFS
- Identifying these molecules could reveal biological differences between patients, help us define ME/CFS subgroups, and ultimately identify potential markers for diagnosis and treatment
- At the **Rosalind Franklin Institute (RFI)**, we have **specialised technology** that can **identify the structure of unknown molecules** – even when only tiny amounts are present



Crystallise molecule(s)



+ *COMPUTATIONAL
PREDICTIONS*

Confirmed
structure of
molecule

Mass Spectrometry and Liquid Chromatography

Electron Microscope

THE PROJECT | a new way to find biomarkers

Limitations Of Traditional Methods

- Uses only **limited information** from the mass spectrometer
- Relies on **AI** to **predict structures**, which can be **inaccurate**
- **No microscope validation** (requires large sample amounts)
- **Often not possible** with patient samples

**KEY
DISEASE
MARKERS
MAY BE
MISSED**

We can find tiny amounts of important molecules and reveal their 3D shapes


**FIND
ROLE IN
DISEASE**

Our Workflow Is More Flexible


1. FIND IMPORTANT MOLECULES



2. ADVANCED STRUCTURAL ANALYSIS



3. MULTI-METHOD VALIDATION



7

The ME/CFS Cohorts We Are Studying:

1. Exercise intervention cohort ⁹



NICOLAUS COPERNICUS
UNIVERSITY
IN TORUŃ

2. Cryotherapy cohort ^{10,11}



NICOLAUS COPERNICUS
UNIVERSITY
IN TORUŃ

3. Post-exertional malaise cohort ¹²



OUR PROGRESS SO FAR | Applying method to disease molecules

1 Our method worked successfully on molecules made in our laboratory


10. Lumsden et al., ChemRxiv (2026)

A. Made the molecules




PRODUCED
32
MOLECULES
AT ONCE


B. Collected their mass spectrometry data




C. Computed their possible structures





D. Confirmed the structures with the microscope




2 We successfully applied our method to an ME/CFS-related molecule




Confirmed as **γ -Glu-Leu** by microscope and fragmentation modelling




It was unclear from computer analysis whether the molecule was **γ -Glu-Leu** or **γ -Glu-Ile**, which are extremely similar



Mass spectrometry data



FUTURE PLANS



```
graph TD; A((FUTURE PLANS)) --- B((Compare different patient groups to find shared disease-related molecules)); A --- C((Find molecules that are different in people with ME/CFS (absent in healthy people))); A --- D((Find out if important molecules are linked to known ME/CFS disease pathways)); A --- E((Test different ways of preparing and analysing the samples to find more molecules));
```

Compare different patient groups to find shared disease-related molecules

Find molecules that are different in people with ME/CFS (absent in healthy people)

Find out if important molecules are linked to known ME/CFS disease pathways

Test different ways of preparing and analysing the samples to find more molecules



Thanks for listening!

CITATIONS

- (1) **Nature Portfolio (2025)** *Metabolomics*. Nature Portfolio.
- (2) **The Rosalind Franklin Institute**. *The Rosalind Franklin Institute: New pathways to improve health*. Available at <https://www.rfi.ac.uk/>
- (3) **Hitachi High-Tech (2026)** *Transmission Electron Microscope HT7800 Series*. Hitachi High-Tech.
- (4) **World Pharma Today (2022)** *Bruker launches timsTOF SCP for unbiased single cell 4D-proteomics and next-gen timsTOF Pro 2 with unprecedented proteomic depth*
- (5) **Oxford University Hospitals NHS Foundation Trust (2026)** *History of the John Radcliffe Hospital*. Oxford University Hospitals NHS Foundation Trust.
- (6) **Prenetics (2026)** *Early Detection | Insighta*. Prenetics.
- (7) **Created with BioRender**. *Biorender*. Available at <https://www.biorender.com>
- (8) **Kromtekindo Utama (2021)** *AQUITY H-Class PLUS System*. Available at <https://kromtekindo.com/2021/12/30/acquity-uplc-h-class-plus-system/>
- (9) **Zhao, L. et al. (2026)** 'The efficacy of exercise in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and meta-analysis', *Journal of Psychosomatic Research*, 207, 112677.
- (10) **Kujawski, S. et al. (2023)** 'Effects of whole-body cryotherapy and static stretching are maintained 4 weeks after treatment in most patients with chronic fatigue syndrome', *Cryobiology*. doi: 10.1016/j.cryobiol.2023.05.003.
- (11) **Kujawski, S. et al. (2022)** 'Combination of whole body cryotherapy with static stretching exercises reduces fatigue and improves functioning of the autonomic nervous system in Chronic Fatigue Syndrome', *Journal of Translational Medicine*, 20, 279.
- (12) **Pears, K. (2023)** *ME Association Research Review: Post-Exertional Malaise (PEM) in ME/CFS and Long Covid*. The ME Association. Available at: <https://meassociation.org.uk/2023/12/me-association-research-review-post-exertional-malaise-pem/>
- (13) **OpenAI (2026)** *ChatGPT (GPT-5) [Large language model]*. OpenAI.
- (14) **Lumsden et al., 2026**. *Integrating Ion Mobility-Resolved Tandem Mass Spectrometry and Microcrystal Electron Diffraction for Structural Elucidation*. ChemRxiv.